DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Total Debt
Short-term and long-term borrowings combined.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 32.9% from a year ago
Total debt stood at $212K at the end of Q1 FY2026, down 32.9% from a year earlier and down 11.7% from the prior quarter. Over 3 fiscal years it compounded at -20.0% a year.
Context
- Total debt amounted to 0.4% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -32.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 240K USD
- Year-over-year change
- -29.4%
- 4-year CAGR
- +46.6%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 240K | -29.4% |
| FY2024 | 2024-12-31 | 340K | -15.0% |
| FY2023 | 2023-12-31 | 400K | -14.7% |
| FY2022 | 2022-12-31 | 469K | +801.9% |
| FY2021 | 2021-12-31 | 52K | — |
Total Debt vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 total debt of $212K is the lowest of the 7 companies compared; the peer median is $8.26M.
- Its year-over-year change of -32.9% is the 4th highest of 7, against a peer median of -14.3%.
- Total debt amounts to 0.4% of total assets for DMAC, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $61.22M | +137.1% | -10.1% | 14.6% | |
| Jun 2026 | $27.51M | -40.9% | -15.2% | 2.4% | |
| Mar 2026 | $12.5M | -76.9% | +29.4% | 3.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $4.03M | -60.9% | +31.1% | 1.0% |
| Mar 2026 | $3.78M | +12.3% | +18.9% | 1.3% | |
| Mar 2026 | $941K | +35.6% | -0.3% | 1.5% | |
| Mar 2026 | $212K | -32.9% | -20.0% | 0.4% | |
| Peer median (excluding DMAC) | $8.26M | -14.3% | +9.3% | 1.9% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.